University of Southern California
usc.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
782
Active
162
Phase 3
17
Total enrollment
1,415,472
Pipeline matrix
Showing 40 of 75 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Adjuvant analgesia | — | — | — | — | — | 1 | |
| Control | — | — | — | — | — | 1 | |
| Zolpidem Tartrate 10 mg | — | — | — | — | — | 1 | |
| Clomiphene Citrate | — | — | — | — | — | 1 | |
| Cefixime 400mg | — | — | — | — | — | 1 | |
| benzathine penicillin | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | 6 | ||
| Recombinant EphB4-HSA Fusion Protein | — | — | — | — | 7 | ||
| Guadecitabine | — | — | — | — | 3 | ||
| Tirzepatide | — | — | — | — | — | 2 | |
| Cemiplimab | — | — | — | — | 2 | ||
| Atezolizumab | — | — | — | — | 2 | ||
| Capecitabine | — | — | — | — | 4 | ||
| Cytarabine | — | — | — | — | 4 | ||
| regorafenib | — | — | — | — | — | 2 | |
| Gentamicin Sulfate | — | — | — | — | — | 2 | |
| Bortezomib | — | — | — | — | 2 | ||
| Metformin Extended Release Oral | — | — | — | — | — | 1 | |
| 80mg/day Ketamine HCl Prolonged Release | — | — | — | — | — | 1 | |
| 160mg/day Ketamine HCl Prolonged Release | — | — | — | — | — | 1 | |
| Sarilumab 150mg or 200 mg plus Capecitabine | — | — | — | — | — | 1 | |
| Sarilumab 150mg plus Capecitabine | — | — | — | — | — | 1 | |
| Atezolizumab and Recombinant Human Hyaluronidase | — | — | — | — | — | 1 | |
| Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg | — | — | — | — | — | 1 | |
| Angiotensin Receptor Blockers | — | — | — | — | — | 1 | |
| Hydrophilic Statins or Non-Statin Alternative | — | — | — | — | — | 1 | |
| Idarubicin | — | — | — | — | — | 1 | |
| Pevonedistat | — | — | — | — | — | 1 | |
| Psilocybin plus mindfulness training | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | — | — | 1 | |
| Danazol Pill | — | — | — | — | — | 1 | |
| Anti-OX40 Antibody PF-04518600 | — | — | — | — | — | 1 | |
| Axitinib | — | — | — | — | — | 1 | |
| Enzalutamide | — | — | — | — | — | 1 | |
| Group B, Linezolid 10d | — | — | — | — | — | 1 | |
| Group A, Penicillin | — | — | — | — | — | 1 | |
| T2:C100 | — | — | — | — | — | 1 | |
| Minocyclin | — | — | — | — | — | 1 | |
| Pelareorep | — | — | — | — | — | 1 | |
| Imiquimod | — | — | — | — | — | 1 |
35 more active programs hidden
Next readouts
- 2020-07-30
- 2021-04-01
- 2021-09-27
- 2023-02-27
- 2025-08-31
- 2025-11
- 2025-12-31
- 2026-04-30
- 2026-04-30
- 2026-08
Top conditions
- Obesity26
- Depression16
- Stage IIIA Breast Cancer13
- Stage II Breast Cancer11
- Stage IIIB Breast Cancer11
- Colorectal Cancer11
- Breast Carcinoma10
- Stage IA Breast Cancer10
Frequently asked questions about University of Southern California
- How many clinical trials does University of Southern California have on ClinicalTrials.gov?
- University of Southern California is listed as the lead sponsor on 782 clinical trials in ClinicalTrials.gov, 162 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Southern California's trials are in Phase 3?
- 17 of University of Southern California's trials are in Phase 3, spread across 75 active drug programs.
- What therapeutic areas does University of Southern California focus on?
- University of Southern California's most-studied conditions on ClinicalTrials.gov are Obesity, Depression, Stage IIIA Breast Cancer, Stage II Breast Cancer, Stage IIIB Breast Cancer.
- When are University of Southern California's next clinical trial readouts?
- University of Southern California has 10 upcoming primary-completion readouts tracked here; the soonest is “Gentamicin for Junctional Epidermolysis Bullosa”, expected around 2020-07-30.